NEPH (Nephros) Cash-to-Debt : 2.67 (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Nephros Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nephros's cash to debt ratio for the quarter that ended in Dec. 2024 was 2.67.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nephros could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Nephros's Cash-to-Debt or its related term are showing as below:

NEPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36 Med: 2.51 Max: No Debt
Current: 2.67

During the past 13 years, Nephros's highest Cash to Debt Ratio was No Debt. The lowest was 0.36. And the median was 2.51.

NEPH's Cash-to-Debt is ranked better than
55.57% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 1.825 vs NEPH: 2.67

Nephros Cash-to-Debt Historical Data

The historical data trend for Nephros's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nephros Cash-to-Debt Chart

Nephros Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

3.80

6.97

3.33

2.35

2.67

Nephros Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															2.35	2.13	1.95	1.65	2.67

Competitive Comparison of Nephros's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Nephros's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nephros's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nephros's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Nephros Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nephros's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.76	/	(0.348	+	1.063)
	=	2.66

Nephros's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.76	/	(0.348	+	1.063)
	=	2.66

Nephros (NAS:NEPH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nephros Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nephros's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nephros Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

NPJP:Germany NPJP:Germany

Address

380 Lackawanna Place, South Orange, NJ, USA, 07079

Website

https://www.nephros.com

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.

Executives

Arthur H Amron	director	C/O WEXFORD CAPITAL LP, 777 WEST PUTNAM AVENUE, FIRST FLOOR, GREENWICH CT 06830
Banks Robert R. Jr.	director, officer: President and CEO	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel	officer: Chief Financial Officer	320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo	officer: Chief Marketing Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor	officer: Chief Financial Officer	380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp	director, 10 percent owner	777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino	officer: Chief Financial Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans	director, officer: President and CEO	C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079